In:
Therapeutic Apheresis and Dialysis, Wiley, Vol. 17, No. S1 ( 2013-04), p. 9-14
Abstract:
Data of 36 months were accumulated regarding the effects of lanthanum carbonate ( LA ) on serum phosphate concentrations in dialysis patients. Fifty‐three patients (average age and dialysis history 58.4 years and 9.1 years) were included in this study who have been receiving outpatient treatment since M arch 2009, and who have been unable to maintain serum phosphate concentrations of ≤6.0 mg/dL via traditional therapeutic agents used for hyperphosphatemia. Patients were given dosage of LA in addition to, or instead of, co‐hyperphosphatemia treatments already being received. Mean dosages of calcium carbonate ( CC ) and sevelamer hydrochloride ( SH ) before starting LA administration were 1301.9 mg and 2462.3 mg, respectively. Dosage of LA for all cases was 750 mg at initial dose; 1528.3 mg at 5 months; and 1416.7 mg at 30 months. Dosage of other phosphate binders were 905.7 mg of CC and 820.8 mg of SH at 5 months; and 687.5 mg of CC and 1031.3 mg of SH at 30 months. Serum phosphorus levels (P levels) were significantly decreased at 1 month of LA administration, and continued until 30 months of L a treatment. These results suggest that LA successfully controlled serum P and C a concentrations simultaneously within target ranges without affecting serum intact parathyroid hormone concentration, although further long‐term prospective cohort study on LA would be required.
Type of Medium:
Online Resource
ISSN:
1744-9979
,
1744-9987
DOI:
10.1111/tap.2013.17.issue-s1
DOI:
10.1111/1744-9987.12043
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2010864-3
Permalink